compensation for distribution of the Company’s products through independent pharmacies, totaling approximately Baht 22.63 million which mounted year-on-year by Baht 19 .4 4 million ( the employment of Zuellig
products through independent pharmacies, totaling approximately Baht 22.63 million which mounted year-on-year by Baht 19 .4 4 million ( the employment of Zuellig Pharma Ltd. took effect as from September 1
had total expenses and impairment loss of 4,325 million Baht (350% of total revenues); increased by 235% as compared to the year of 1,291 million Baht. This comprised of: (1) selling expenses of 454
.2546 including additional announcement. 2. The meeting appoints the independent financial advisor. Due to the disposition of assets between the company and the seller is the connected transaction which
this quarter. As a result, the Company reported net loss of Baht 4.6 million or decreased Baht 39.9 million, compared with QoQ. Loss per share was Baht 0.21. In the nine-month period of 2017, the Company
impairment loss of 8,175 million Baht (88% of total revenues); increased by 83.7% as compared to the year of 4,451 million Baht. This comprised of: (1) cost of sales of residential condominium units of 3,304
% Administrative expenses (663.1) (25.7%) (1,083.8) (28.4%) (420.7) 63.5% Other income 489.6 19.0% 199.8 5.2% (289.8) (59.2%) Share of profit (loss) from investment in an associate and joint ventures 83.6 3.2% 20.2
strictly for reference. 2 Notification of the Office of Securities and Exchange Commission No. SorThor. 7/2557 Re: Rules on Appointing Independent Director of an Intermediary _____________________________ By
Notification of the Capital Market Supervisory Board Notification of the Office of Securities and Exchange Commission No. SorThor. 7/2557 Re: Rules on Appointing Independent Director of an